CASE STUDY PRA Instrumental in Meeting Stringent Timelines in Ebola Vaccine Trial Organized Approach Key to Efficient Study Start-upPRA Instrumental in Meeting Stringent Timelines in Ebola Vaccine Trial Organized Approach Key to Efficient Study Start-up Primary Endpoint The key immunogenicity endpoint was geometric mean titer at Day 28 post-vaccination for antibody titers as measured in all subjects. PRA Services Study start-up activities including Clinical Trial Research Agreement, site budget negotiations, ICF reviews, and IRB approval coordination Indication Ebola Drug Class Vaccine Biologic Study Phase III Business Segment Strategic Solutions Regions North America STUDY DESCRIPTION A Phase III, randomized, placebo-controlled, clinical trial to study the safety

Join for free to read